<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02573584</url>
  </required_header>
  <id_info>
    <org_study_id>201500864</org_study_id>
    <nct_id>NCT02573584</nct_id>
  </id_info>
  <brief_title>Vascular Fingerprint Validation Study</brief_title>
  <official_title>Vascular Fingerprint to Identify Patients at Risk for Arterial Cardiovascular Events Within the First Year After Start of Cisplatin-based Chemotherapy for Testicular Cancer: a Validation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The vascular fingerprint is a simple selection tool to identify testicular cancer patients
      with a high risk of arterial cardiovascular events during and in the first year after
      cisplatin chemotherapy. Eventually, this selection method allows a relative small randomized
      intervention study with i.e. LMWH during chemotherapy to prove the effectiveness and safety
      in lowering the chance of an arterial cardiovascular event.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since the introduction of cisplatin in the late seventies (1), the prognosis of metastatic
      testicular cancer patients has dramatically improved, with long-term survival rates of 80-90%
      (2). However, cure rates are compromised by the increased risk of cardiovascular events
      (3-5). Approximately 1-5% of the patients with metastatic testicular cancer develop arterial
      cardiovascular events during or shortly after cisplatin- and bleomycin containing
      chemotherapy (3-7). Arterial cardiovascular events include ischemic stroke and myocardial
      infarction. These arterial events are a source of serious treatment-induced morbidity and
      mortality as recently clearly confirmed by Fung (8). No established standard prophylaxis is
      available. There is an unmet need to have the possibility to identify high risk patients
      before start of chemotherapy in whom prophylactic anti-coagulant treatment may prevent events
      (9). An identification tool could maximize the benefit of an intervention without introducing
      too much unnecessary harm: preventive interventions also carry risk.

      Recent data from the investigators' cancer center showed that before chemotherapy 22% of the
      metastatic cancer patients had ≥3 of the following 5 traditional cardiovascular risk factors
      present (high risk vascular fingerprint, figure 1): overweight, smoking, hypertension,
      dyslipidemia and impaired blood glucose. These patients had an increased risk to develop
      arterial events during or early after chemotherapy: 19% of the patients with a high risk
      vascular fingerprint developed an arterial cardiovascular event whereas only 2% of the
      patients with ≤2 risk factors developed an event . The vascular fingerprint seems an easy
      method to identify which metastatic testicular cancer patients are at a high risk for early
      arterial events and who may benefit from prophylaxis with for example low molecular weight
      heparins (LMWHs). To be used in the clinic these data need to be confirmed in an independent
      cohort.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of arterial cardiovascular events</measure>
    <time_frame>first year after start of chemotherapy</time_frame>
    <description>Primary outcome is development of arterial cardiovascular events within the first year after start of chemotherapy. Events taken into account are: myocardial infarction (WHO ICD-10 I20-I25), ischemic cerebrovascular accidents (WHO ICD-10 I63-I66 and G45) or infarction in other specific organ systems (WHO ICD-10 K76.3, K55, D73.5, M62.2, N28.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>first year after start of chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to testicular cancer treatment (no evidence of disease / relapse / no response to treatment)</measure>
    <time_frame>first year after start of chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of venous thromboembolic events (VTE) (WHO ICD-10 I26, I80-82)</measure>
    <time_frame>first year after start of chemotherapy</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Testicular Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Newly diagnosed testicular cancer patients before start of chemotherapy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of metastatic TC and an indication to start with first-line cisplatin-based
             chemotherapy for metastatic TC

          2. Classified into IGCCCG good or intermediate prognosis group

          3. Younger than 50 years of age at start of chemotherapy

          4. Signed informed consent

        Exclusion Criteria:

          1. History of previous cardiovascular disease

          2. Retroperitoneal mass &gt; 5 cm

          3. Indication for anticoagulant therapy at start of chemotherapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jourik A Gietema, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jourik A Gietema, MD, PhD</last_name>
    <phone>+31 503616161</phone>
    <email>j.a.gietema@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sjoukje Lubberts, MD</last_name>
    <phone>+31 503616161</phone>
    <email>s.lubberts@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis (NKI-AVL)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Kerst, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.A. Gietema, MD PhD</last_name>
      <email>j.a.gietema@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>S. Lubberts, MD</last_name>
      <email>s.lubberts@umcg.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center (MUMC)</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Aarts, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Portuges de Oncologia Francisco Gentil (IPOLFG)</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Brito, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UniversitatsSpital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Beyer, MD PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>C. Fankhauser, MD PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977 Sep;87(3):293-8.</citation>
    <PMID>71004</PMID>
  </results_reference>
  <results_reference>
    <citation>DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71. doi: 10.3322/caac.21235. Epub 2014 Jun 1. Review.</citation>
    <PMID>24890451</PMID>
  </results_reference>
  <results_reference>
    <citation>Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, Cleton FJ, Osanto S. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000 May;18(10):2169-78. Review.</citation>
    <PMID>10811682</PMID>
  </results_reference>
  <results_reference>
    <citation>Piketty AC, Fléchon A, Laplanche A, Nouyrigat E, Droz JP, Théodore C, Fizazi K. The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer. 2005 Oct 17;93(8):909-14.</citation>
    <PMID>16205699</PMID>
  </results_reference>
  <results_reference>
    <citation>Nuver J, Smit AJ, van der Meer J, van den Berg MP, van der Graaf WT, Meinardi MT, Sleijfer DT, Hoekstra HJ, van Gessel AI, van Roon AM, Gietema JA. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol. 2005 Dec 20;23(36):9130-7. Epub 2005 Nov 21.</citation>
    <PMID>16301596</PMID>
  </results_reference>
  <results_reference>
    <citation>Dieckmann KP, Struss WJ, Budde U. Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour. Anticancer Res. 2011 Dec;31(12):4501-5.</citation>
    <PMID>22199322</PMID>
  </results_reference>
  <results_reference>
    <citation>Dieckmann KP, Gerl A, Witt J, Hartmann JT; German Testicular Cancer Study Group. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol. 2010 Aug;21(8):1607-11. doi: 10.1093/annonc/mdp597. Epub 2010 Jan 12.</citation>
    <PMID>20067918</PMID>
  </results_reference>
  <results_reference>
    <citation>Fung C, Fossa SD, Milano MT, Sahasrabudhe DM, Peterson DR, Travis LB. Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study. J Clin Oncol. 2015 Oct 1;33(28):3105-15. doi: 10.1200/JCO.2014.60.3654. Epub 2015 Aug 3.</citation>
    <PMID>26240226</PMID>
  </results_reference>
  <results_reference>
    <citation>Ramos JD, Yu EY. Cardiovascular Mortality in Testicular Nonseminomatous Germ Cell Tumors: Does Statistical Significance Imply Clinical Significance? J Clin Oncol. 2015 Oct 1;33(28):3075-7. doi: 10.1200/JCO.2015.62.7398. Epub 2015 Aug 24.</citation>
    <PMID>26304903</PMID>
  </results_reference>
  <results_reference>
    <citation>Lubberts S, Boer H, Altena R, Meijer C, van Roon AM, Zwart N, Oosting SF, Kamphuisen PW, Nuver J, Smit AJ, Mulder AB, Lefrandt JD, Gietema JA. Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy. Eur J Cancer. 2016 Aug;63:180-8. doi: 10.1016/j.ejca.2016.05.022. Epub 2016 Jun 17.</citation>
    <PMID>27322917</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2015</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>J.A. Gietema</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testicular Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

